Larimar Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beloranib (ZGN-440) / Larimar Therap
2015-000660-33: A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placebo

 
3
25
Europe
Subcutaneous Beloranib in Suspension, ZGN-440,
Zafgen Inc., Zafgen Inc.
Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
 
 
nomlabofusp (CTI-1601) / Larimar Therap
NCT05579691: A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Completed
2
28
US
CTI-1601, Placebo
Larimar Therapeutics, Inc.
Friedreich Ataxia
12/23
12/23
Jive, NCT06447025: An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia

Enrolling by invitation
2
75
US
CTI-1601, Nomlabofusp
Larimar Therapeutics, Inc.
Friedreich Ataxia
01/27
01/27
NCT06681766: A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia

Recruiting
1
30
US
Nomlabofusp, CTI-1601, Placebo, CTI-1601 Placebo, Nomlabofusp Placebo
Larimar Therapeutics, Inc.
Friedreich Ataxia
08/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
beloranib (ZGN-440) / Larimar Therap
2015-000660-33: A clinical trial to study the efficacy and safety of an investigational medication, beloranib, in treatment of food-related behaviour and weight in obese individuals with Prader-Willi Syndrome by comparison with placebo

 
3
25
Europe
Subcutaneous Beloranib in Suspension, ZGN-440,
Zafgen Inc., Zafgen Inc.
Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
 
 
nomlabofusp (CTI-1601) / Larimar Therap
NCT05579691: A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Completed
2
28
US
CTI-1601, Placebo
Larimar Therapeutics, Inc.
Friedreich Ataxia
12/23
12/23
Jive, NCT06447025: An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia

Enrolling by invitation
2
75
US
CTI-1601, Nomlabofusp
Larimar Therapeutics, Inc.
Friedreich Ataxia
01/27
01/27
NCT06681766: A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia

Recruiting
1
30
US
Nomlabofusp, CTI-1601, Placebo, CTI-1601 Placebo, Nomlabofusp Placebo
Larimar Therapeutics, Inc.
Friedreich Ataxia
08/25
08/25

Download Options